Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer
Journal Title
Frontiers in Oncology
Publication Type
Research article
Abstract
BACKGROUND: Lutetium-177 [(177)Lu]-PSMA-617 is a targeted radioligand that binds to prostate-specific membrane antigen (PSMA) and delivers radiation to metastatic prostate cancer. The presence of PSMA-negative/FDG-positive metastases can preclude patients from being eligible for this treatment. Biology-guided radiotherapy (BgRT) is a treatment modality that utilises tumour PET emissions to guide external beam radiotherapy. The feasibility of combining BgRT and Lutetium-177 [(177)Lu]-PSMA-617 for patients with PSMA-negative/FDG-positive metastatic prostate cancer was explored. MATERIALS AND METHODS: All patients excluded from the LuPSMA clinical trial (ID: ANZCTR12615000912583) due to PSMA/FDG discordance were retrospectively reviewed. A hypothetical workflow where PSMA-negative/FDG-positive metastases would be treated with BgRT whilst PSMA-positive metastases would be treated with Lutetium-177 [(177)Lu]-PSMA-617 was considered. Gross tumour volume (GTV) of PSMA-negative/FDG-positive tumours were delineated on the CT component of the FDG PET/CT scan. Tumours were deemed suitable for BgRT if (1) normalised SUV (nSUV), defined as the ratio of maximum SUV (SUVmax) inside the GTV to mean SUV inside a 5 mm/10 mm/20 mm margin expansion of the GTV, was larger than a pre-specified nSUV threshold and (2) there was no PET avidity inside the margin expansion. RESULTS: In 75 patients screened for Lutetium-177 [(177)Lu]-PSMA-617 treatment, 6 patients were excluded due to PSMA/FDG discordance and 89 PSMA-negative/FDG-positive targets were identified. GTV volumes ranged from 0.3 cm(3) to 186 cm(3) (median GTV volume = 4.3 cm(3), IQR = 2.2 cm(3) - 7.4 cm(3)). SUVmax inside GTVs ranged between 3 and 12 (median SUVmax = 4.8, IQR = 3.9 - 6.2). With nSUV >/= 3, 67%/54%/39% of all GTVs were suitable for BgRT within 5 mm/10 mm/20 mm from the tumour. Bone and lung metastases were the best candidates for BgRT (40%/27% of all tumours suitable for BgRT with nSUV >/= 3 within 5 mm from the GTV were bone/lung GTVs). CONCLUSIONS: Combined BgRT/Lutetium-177 [(177)Lu]-PSMA-617 therapy is feasible for patients with PSMA/FDG discordant metastases.
Publisher
Frontiers
Keywords
BgRT; LuPSMA; Psma; mCRPC; theranostics
Department(s)
Physical Sciences; Radiation Oncology; Cancer Imaging
PubMed ID
36994211
Open Access at Publisher's Site
https://doi.org/10.3389/fonc.2023.1134884
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-08-15 07:31:25
Last Modified: 2023-08-15 07:32:14

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙